Tadaaki Ohgi

This inventor holds 30 USPTO granted patents and 8 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Nucleic Acid Technology. Top assignees: Bonac Corporation, Nippon Shinyaku Company, Ltd., Tokyo Medical University. Active years: 1985-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tadaaki Ohgi. Retrieved from https://idiyas.com/inventor/tadaaki-ohgi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 8)

% Patents Active = 60.0

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 18)

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 284(Granted Patents)

Location History:

Nagaokakyo, JP (1985 - 1986)
Shiga, JP (1997 - 1999)
Otsu, JP (1994 - 2000)
Ibaraki, JP (2004 - 2007)
Tsuchiura, JP (2007 - 2014)
Fukuoka, JP (2015 - 2016)
Kurume, JP (2014 - 2024)

Company Filing History:

Nippon Shinyaku Company, Ltd.

patents

1 out of 11

Tokyo Medical University

patents

4. 1 out of 3,581

Toray Industries, Inc.

patents

where one patent can have more than one assignee

Years Active: 1985-2024

Loading Chart...

Areas of Expertise:

Single-Stranded RNA

Gene Expression

Micro-RNA Inhibitor

Glycoside Compounds

Nucleic Acid Molecules

Phosphoramidite Compound

Drug Carrier

Peptide Derivatives

Triterpene Derivatives

Antiviral Compounds

Cyclic Derivatives

Triazine Derivatives

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11891602 - Method of producing hairpin single-stranded RNA molecules (2024-02-06),

2. 11518994 - Artificial single guide RNA and use thereof (2022-12-06),

3. 11142769 - Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability (2021-10-12),

4. 11027023 - Natural type miRNA for controlling gene expression, and use of same (2021-06-08),

5. 10934542 - Artificial match-type miRNA for controlling gene expression and use therefor (2021-03-02),

6. 10377788 - Method for producing glycoside compounds (2019-08-13),

7. 10238752 - Single-stranded nucleic acid molecule for regulating expression of gene having delivering function (2019-03-26),

8. 10233446 - Micro-RNA inhibitor (2019-03-19),

9. 9663784 - Single-stranded nucleic acid molecule for regulating expression of gene having delivering function (2017-05-30),

10. 9528111 - Single-stranded nucleic acid molecule having amino acid backbone (2016-12-27),

11. 9404108 - Micro-RMA inhibitor (2016-08-02),

12. 9315799 - Process for preparing phosphate compound bearing isotope (2016-04-19),

13. 9206422 - Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton (2015-12-08),

14. 9200278 - Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton (2015-12-01),

15. 8785121 - Single-stranded nucleic acid molecule for controlling gene expression (2014-07-22),

Title: **The Innovative Journey of Tadaaki Ohgi**

Introduction

Tadaaki Ohgi is a notable inventor based in Kurume, Japan, recognized for his significant contributions to the field of molecular biology. With an impressive portfolio of 30 patents, Ohgi has made substantial advancements in the development of RNA molecules and gene expression technology. His inventive mind continues to drive innovations in genetic research and therapeutic applications.

Latest Patents

Ohgi's recent patents showcase his expertise in RNA technology. One of his significant inventions is a **method of producing hairpin single-stranded RNA molecules**. This method facilitates the creation of RNA capable of inhibiting the expression of target genes by utilizing innovative chemical reactions. The process involves reacting specific oligo-RNA molecules in a carefully controlled solvent environment that includes dehydrating agents to enhance efficacy.

Another remarkable contribution is his patent on **artificial single guide RNA (sgRNA)** and its utilization within the CRISPR/Cas9 genome-editing system. This invention enhances the stability and activity of sgRNA, even when modified with amino acid derivative linkers, thereby expanding the potential applications of CRISPR technology in gene editing.

Career Highlights

Throughout his career, Tadaaki Ohgi has worked with esteemed organizations, notably Bonac Corporation and Nippon Shinyaku Company, Ltd. His tenure in these companies has allowed him to collaborate on pioneering research that bridges the gap between molecular biology and practical applications in medicine.

Collaborations

Ohgi has had the privilege of collaborating with talented individuals in his field, including notable coworkers Tomohiro Hamasaki and Eriko Aoki. These partnerships have fostered a dynamic exchange of ideas, contributing to the advancement of technological innovations in RNA research.

Conclusion

Tadaaki Ohgi's work exemplifies the spirit of innovation within the scientific community. His patents have not only advanced our understanding of RNA mechanisms but also provided critical tools for gene editing and therapeutic interventions. As he continues to explore new frontiers in molecular biology, there is no doubt that Ohgi will remain a pivotal figure in the ongoing evolution of genetic research.

Profile summary based on public USPTO records.